Revance Therapeutics (RVNC) Misses Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
August 9, 2022 4:05 PM EDTPDUFA date of September 8, 2022 for DaxibotulinumtoxinA for Injection in glabellar lines Reinspection of manufacturing facility completed as part of Class II BLA resubmission for DaxibotulinumtoxinA for Injection in glabellar lines Second quarter total revenue of $28.4 million, with RHA® Collection revenue of $25.5 million Aesthetic accounts across products and services totaled over 4,000 at quarter-end Revance launches RHA® Redensity for the treatment of moderate to severe perioral rhytids (lip lines) Conference call and webcast today at 4:30 p.m. ET.
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics,... More
